2 Biotech Stocks to Have On Your Radar Into the New Year

CORAL GABLES, FL / ACCESSWIRE / December 11, 2017 / December will be a critical month for the markets as investors wait anxiously to see if this bullish trend will continue its momentum into 2018. Two sectors that have been the main focus thus far this year are technology and biotechnology. For biotech stocks, the proposed tax reforms could have a huge impact for investors. The reform aims to trim the corporate tax rate from 35% to 20%, which can increase profits of biotech companies. The change in tax code will also allow companies to bring back large amounts of cash that is being held overseas at a one-time tax rate of 10%. With that being said, here are two biotech stocks to watch in December.

GT Biophama, Inc. (OTCQB: GTBP) is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of novel cancer immunotherapy treatments. The company recently announced it has started its FDA phase 1 clinical trials for its myasthenia gravis, GTP-004 candidate.

GT Biopharma Chief Executive Officer, Dr. Kathleen Clarence-Smith, stated, “I am very pleased that GT Biopharma’s first clinical trial in patients with myasthenia gravis has started and I have high hopes that the GTP-004 drug will bring substantial help to patients. The start of this trial underscores our commitment to patients with neurological disease.”

This news comes off the heels of previous announcements that the company has added big pharma experience to its management team with years of experience of taking treatments from clinical trials to market. Over the last 30 trading days, GTBP has been trading in the price range between $5.00 and $6.00.

Verastem, Inc. (NASDAQ: VSTM), a biopharmaceutical company that is focused on developing drugs for the cancer market, saw a hike of 36.55% in pre-market trading action after the company announced positive results from a Phase 3 DUO study that evaluated the safety and efficacy of duvelisib, its leukemia treatment.

“CLL/SLL mostly affects elderly patients and many are unable or unwilling to be hospitalized or come into the clinic for frequent IV infusions. The CLL/SLL treatment landscape, therefore, is moving away from chemotherapies and toward more targeted, preferably oral regimens,” stated Diep Le, MD, PhD, Chief Medical Officer of Verastem.

About BiotechStocks.com

BIOTECHSTOCKS.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,000,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017, now extended to December 31, 2017, to publicly disseminate information about GTBP. We own zero shares.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither BTS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://biotechstocks.com.

NO WARRANTY

BTS, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Contact:

news@biotechstocks.com

SOURCE: BiotechStocks.com

ReleaseID: 484046